Skip to main content

Advertisement

SpringerLink
Log in

Malignancy and systemic lupus erythematosus

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The association of malignancy with systemic lupus erythematosus (SLE) has been investigated for years. The findings of cohort studies lend support for an increased risk of malignancy in SLE but are difficult to interpret definitively. In addition, several cohort studies have suggested an increased risk of non-Hodgkin’s lymphoma but with imprecise estimation. There is inadequate evidence for any conclusions about the risk of solid tumors in these patients. A multicenter international research effort is in progress to elucidate these issues and to establish the role of exposures such as cytotoxic or immunomodulatory therapy. The recommendations advocated for cancer screening policies and for minimizing known risk factors for cancer in the general population should not be neglected in persons with SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G: Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000, 27:685–691.

    PubMed  CAS  Google Scholar 

  2. Sigureirsson B, Lindelof B, Edhag O, Allander E: Risk of cancer in patients with dermatomyositis or polymyositis: a population based study. N Engl J Med 1992, 326:363–367.

    Article  Google Scholar 

  3. McCurley TE, Collins RD, Ball E: Nodal and extranodal lymphoproliferative disorders in Sjogren’s syndrome: a clinical and immunopathological study. Hum Pathol 1990, 21:482–492.

    Article  PubMed  CAS  Google Scholar 

  4. Roumm AD, Medsger TAJ: Cancer and systemic sclerosis, an epidemiological study. Arthritis Rheum 1985, 28:1336–1340.

    Article  PubMed  CAS  Google Scholar 

  5. Villa AR, Kraus A, Jimenez-Corona A, et al.: Malignant neoplasms in autoimmune rheumatic diseases: examination of the risk of developing a malignancy among five different rheumatic diseases in one institution. J Clin Rheumatol 2000, 6:176–183.

    Article  PubMed  CAS  Google Scholar 

  6. Okada T, Takiura F, Tokushige K, et al.: MHC complex controls clonal proliferation of CD5+ B cells in H-2-congenic New Zealand mouse: a model for B cell chronic lymphocytic leukemia and autoimmune disease. Eur J Immunol 1991, 21:2743–2748.

    Article  PubMed  CAS  Google Scholar 

  7. Kono DH, Burlingame RS, Owens D, et al.: Lupus susceptibility loci in New Zealand mouse. Proc Natl Acad Sci U S A 1994, 91:10168–10172.

    Article  PubMed  CAS  Google Scholar 

  8. Yoshitomo H, Sachiko H, Akinori I, et al.: Susceptibility alleles for aberrant B-1 cell proliferation involved in spontaneously occurring B-cell chronic lymphocytic leukemia in a model of New Zealand White mice. Blood 1998, 92:3772–3779.

    Google Scholar 

  9. Bevan S, Catovsky D, Matutes E, et al.: Linkage analysis for major histocompatibility complex-related genetic susceptibility in familial chronic lymphocytic leukemia. Blood 2000, 96:3982–3984.

    PubMed  CAS  Google Scholar 

  10. Pickering MC, Botto M, Taylor PR, et al.: Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000, 76:227–324.

    PubMed  CAS  Google Scholar 

  11. Makin G, Dive C: Apoptosis and cancer chemotherapy. Trends Cell Biol 2001, 11:S22-S26.

    PubMed  CAS  Google Scholar 

  12. Eguchi K: Apoptosis in autoimmune diseases. Intern Med 2001, 40:275–284.

    PubMed  CAS  Google Scholar 

  13. Miret C, Font J, Molina R, et al.: Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfaTNF) with the activity of systemic lupus erythematosus. Anticancer Res 2001, 21:3053–3061.

    PubMed  CAS  Google Scholar 

  14. Do RK, Chen-Kiang S: Mechanism of BLyS action in B cell immunity. Cytokine Growth Factor Rev 2002, 13:19–25.

    Article  PubMed  CAS  Google Scholar 

  15. Laâbi Y, Strausser A: Lymphocyte survival-ignorance is BLys. Science 2001, 289:883–884.

    Article  Google Scholar 

  16. Datta SK, Schwartz RS: Autoimmunization and graft versus host reactions. Transplant Rev 1976, 31:44–78.

    PubMed  CAS  Google Scholar 

  17. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK: Hyperexpression of CD40 ligand by B and T cells in human lupus. J Clin Invest 1996, 97:2063–2073.

    PubMed  CAS  Google Scholar 

  18. Schattner EJ, Mascarenhas J, Reyfman I, et al.: Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood 1998, 91:2689–2697.

    PubMed  CAS  Google Scholar 

  19. Emilie D, Zou W, Fior R, et al.: Production and roles of IL-6, IL-10, and IL-13 in B-lymphocyte malignancies & in B-lymphocyte hyperactivity of HIV infection and autoimmunity. Methods 1997, 11:133–142.

    Article  PubMed  CAS  Google Scholar 

  20. Jones BM, Liu T, Wong RW: Reduced in vitro production of interferon-gamma, interleukin-4 and interleukin-12 and increased production of interleukin-6, interleukin-10 and tumour necrosis factor-alpha in systemic lupus erythematosus: weak correlations of cytokine production with disease activity. Autoimmunity 1999, 31:117–124.

    Article  PubMed  CAS  Google Scholar 

  21. Wei LH, Kuo ML, Chen CA, et al.: Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol 2001, 82:49–56.

    Article  PubMed  CAS  Google Scholar 

  22. Shariat SF, Andrews B, Kattan MW, et al.: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001, 58:1008–1015.

    Article  PubMed  CAS  Google Scholar 

  23. Fayad L, Cabanillas F, Talpaz M, et al.: High serum interleukin- 6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 2002, 30:563–571.

    Google Scholar 

  24. Hooghe R, Merchav S, Gaidano G, et al.: A role for growth hormone and prolactin in leukaemia and lymphoma? Cell Mol Life Sci 1998, 54:1095–1101.

    Article  PubMed  CAS  Google Scholar 

  25. Dorshkind K, Horseman ND: The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev 2000, 21:292–312.

    Article  PubMed  CAS  Google Scholar 

  26. Isgaard J, Tivesten A: The role of growth hormone and insulinlike growth factor I in the regulation of apoptosis. Growth Horm IGF Res 1999, 9:125–128.

    Article  PubMed  CAS  Google Scholar 

  27. Velkeniers B, Dogusan Z, Naessens F, et al.: Prolactin, growth hormone and the immune system in humans. Cell Mol Life Sci 1998, 54:1102–1108.

    Article  PubMed  CAS  Google Scholar 

  28. Black KA, Zilko PJ, Dawkins RL, et al.: Cancer in connective tissue disease. Arthritis Rheum 1982, 25:1130–1133.

    Article  PubMed  CAS  Google Scholar 

  29. Canoso JJ, Cohen AS: Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis Rheum 1974, 17:383–390.

    Article  PubMed  CAS  Google Scholar 

  30. Dupla ML, Khamashta M, Garcia VP, et al.: Malignancy in SLE: a report of five cases in a series of 96 patients. Lupus 1993, 2:177–181.

    Google Scholar 

  31. Lewis RB, Castor CW, Knisley RE, Bole GG: Frequency of neoplasia in systemic lupus and rheumatoid arthritis. Arthritis Rheum 1976, 19:1256–1260.

    Article  PubMed  CAS  Google Scholar 

  32. Bjornadal L, Lovstrom B, Lundberg I, Ekbom A: Patients with SLE have an increased cancer risk [abstract]. Arthritis Rheum 2000, 43:S165.

    Google Scholar 

  33. Mellemkjaer L, Andersen V, Linet MS, et al.: Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:761–768.

    Article  PubMed  CAS  Google Scholar 

  34. Cibere J, Sibley J, Haga M: Systemic lupus erythematosus and the risk of malignancy. Lupus 2001, 10:394–400. A recent report of the cancer experience of a cohort with systemic lupus erythematosus. The authors review the prevalence of "traditional" risk factors for malignancy such as smoking and obesity within the cohort, concluding that these are unlikely to account for an increase in cancer in patients with lupus compared with the general population.

    Article  PubMed  CAS  Google Scholar 

  35. Pettersson T, Pukkala E, Teppo L, Friman C: Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992, 51:437–439.

    PubMed  CAS  Google Scholar 

  36. Ramsey-Goldman R, Mattai SA, Schilling E, et al.: Increased risk of malignancy in patients with systemic lupus erythematosus. J Invest Med 1998:217-222.

  37. Zoma A, Stonehouse D: Malignancy and SLE in Scotland: a population-based study 1981–1997 [abstract]. Arthritis Rheum 2001, 44:S265.

    Google Scholar 

  38. Bernatsky S: Malignancy in Systemic Lupus Erythematosus [dissertation]. Montreal, Canada: McGill University; 2001.

    Google Scholar 

  39. Sweeney DM, Manzi S, Janosky J, et al.: Risk of malignancy in women with SLE. J Rheumatol 1995, 22:1478–1482.

    PubMed  CAS  Google Scholar 

  40. Sultan SM, Ioannou Y, Isenberg DA: Is there an association of malignancy with SLE? An analysis of 276 patients under long-term review. Rheumatology 2000, 39:1147–1152.

    Article  PubMed  CAS  Google Scholar 

  41. Abu-Shakra M, Gladman DD, Urowitz MB: Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996, 39:1050–1054.

    Article  PubMed  CAS  Google Scholar 

  42. Nived O, Bengtsson A, Jonsen A, et al.: Malignancies during follow-up in an epidemiologically defined SLE inception cohort in southern Sweden. Lupus 2001, 10:500–504.

    Article  PubMed  CAS  Google Scholar 

  43. Tan EM, Cohen AS, Fries JF, et al.: The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982, 25:1271–1277.

    Article  PubMed  CAS  Google Scholar 

  44. Ramsey-Goldman R, Clarke A: Double trouble: are lupus and malignancy associated? Lupus 2001, 10:388–391. An editorial summarizing the literature on malignancy in systemic lupus erythematosus (SLE) and describing the international cohort study in progress examining cancer risk in SLE.

    Article  PubMed  CAS  Google Scholar 

  45. Hughes G: Lupus patients are protected from cancer. Lupus 2002, 10:833–834.

    Article  Google Scholar 

  46. Bernatsky S, Boivin J, Clarke A, Rajan R: Cancer risk in SLE: a meta-analysis [abstract]. Arthritis Rheum 2001, 44:S244.

    Google Scholar 

  47. Yell JA, Burge SM: Warts and lupus erythematosus. Lupus 1993, 2:21–23.

    PubMed  CAS  Google Scholar 

  48. Nyberg G, Eriksson O: Increased incidence of cervical atypia in women with SLE treated with chemotherapy. Arthritis Rheum 1981, 24:648–650.

    Article  PubMed  CAS  Google Scholar 

  49. Bateman H, Yazici Y, Leff L, et al.: Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 2000, 9:542–544.

    Article  PubMed  CAS  Google Scholar 

  50. Jarrett RF, MacKenzie J: Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin’s disease. Semin Hematol 1999, 36:260–269.

    PubMed  CAS  Google Scholar 

  51. James JA, Kaufman KM, Farris AD, et al.: An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997, 100:3019–3026.

    PubMed  CAS  Google Scholar 

  52. James JA, Neas BR, Moser KL, et al.: Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001, 44:1122–1126.

    Article  PubMed  CAS  Google Scholar 

  53. Mattila PS, Aalto SM, Heikkila L, et al.: Malignancies after heart transplantation: presence of Epstein-Barr virus and cytomegalovirus. Clin Transplant 2001, 15:337–342.

    Article  PubMed  CAS  Google Scholar 

  54. Stratta P, Canavese C, Ciccone G, et al.: Correlation between cytomegalovirus infection and Raynaud’s phenomenon in lupus nephritis. Nephron 1999, 82:145–154.

    Article  PubMed  CAS  Google Scholar 

  55. Cras P, Franckx C, Martin J: Primary intracerebral lymphoma in systemic lupus erythematosus treated with immunosuppressives. Clin Neuropathol 1989, 8:200–205.

    PubMed  CAS  Google Scholar 

  56. Elliott RW, Essenhigh DM, Morley AR: Cyclophosphamide treatment of systemic lupus erythematous: risk of bladder cancer exceeds benefits. Br Med J 1982, 284:1160–1161.

    Article  CAS  Google Scholar 

  57. Hehir ME, Sewell JR, Hughes GRV: Reticulum cell sarcoma in azathioprine-treated systemic lupus erythematosus. Ann Rheum Dis 1979, 38:94–95.

    Article  PubMed  CAS  Google Scholar 

  58. Ortiz AM, Gonzalez-Parra E, Alvarez-Costa G, Egido J: Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron 1992, 60:378–379.

    PubMed  CAS  Google Scholar 

  59. Thrasher JB, Miller GJ, Wettlaufer JN: Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J Urol 1990, 143:119–121.

    PubMed  CAS  Google Scholar 

  60. International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. United Kingdom: World Health Organization; 1988.

    Google Scholar 

  61. Casey TP: Azathioprine (Imuran) administration and the development of malignant lymphoma in NZB mouse. Clin Exp Immunol 1968, 3:305–312.

    PubMed  CAS  Google Scholar 

  62. Kyllonen L, Salmela K, Pukkala E: Cancer incidence in a kidney-transplanted population. Transpl Int 2000, 13:S394-S398.

    Article  PubMed  Google Scholar 

  63. Opelz G, Henderson R: Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993, 342:1514–1516.

    Article  PubMed  CAS  Google Scholar 

  64. Bernatsky S, Clarke A, St. Pierre Y, et al.: The prevalence of factors influencing cancer risk in lupus [abstract]. Arthritis Rheum 2001, 44:S244.

    Google Scholar 

  65. Bruce IN, Gladman DD, Urowitz MB: Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 1998, 16:435–440.

    PubMed  CAS  Google Scholar 

  66. International Agency for Research on Cancer: Facts and Figures of Cancer in the European Community. Lyon: World Health Organization; 1993.

    Google Scholar 

  67. NIH Consensus Development Panel on Ovarian Cancer: Ovarian cancer: screening, treatment, and followup. NIH Consensus Statement. JAMA 1994, 273:491–497.

    Google Scholar 

  68. Julkunen HA, Kaaja R, Friman C: Contraceptive practice in women with systemic lupus erythematosus. Br J Rheumatol 1993, 32:227–230.

    Article  PubMed  CAS  Google Scholar 

  69. Petri M, Perez-Gutthann S, Spence D, Hochberg MC: Risk factors for coronary artery disease in patients with SLE. Am J Med 1992, 93:513–519.

    Article  PubMed  CAS  Google Scholar 

  70. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 1987, 257:796-800.

  71. The reduction in risk of ovarian cancer associated with oral contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987, 316:650-655.

  72. Dhar J, Kmak D, Bhan R, et al.: Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. Gynecol Oncol 2001, 82:4–6. The most recent of several reports of increased cervical atypia in patients with systemic lupus erythematosus. A retrospective analysis of 29 patients with lupus consecutively presenting for Papanicolaou smears were found to have a greater incidence of cervical dysplasia compared with controls. Serial observation revealed cervical dysplasia in nearly 50% of the patients.

    Article  PubMed  CAS  Google Scholar 

  73. Bowles KE, Wynne C, Baime MJ: Screening for cancer in the patient with rheumatic disease. Rheum Dis Clin North Am 1999, 25:719–744. A helpful review of recommendations regarding cancer screening.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Arthritis, Northwestern University, Ward 3-315, 303 East Chicago Avenue, 60611-3088, Chicago, IL, USA

    Rosalind Ramsey-Goldman MD, DrPH

Authors
  1. Sasha Bernatsky MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ann Clarke MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rosalind Ramsey-Goldman MD, DrPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernatsky, S., Clarke, A. & Ramsey-Goldman, R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 4, 351–358 (2002). https://doi.org/10.1007/s11926-002-0045-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-002-0045-6

Keywords

Search

Navigation